Laurine Bow, PhD
Associate Professor of Surgery (Transplant)DownloadHi-Res Photo
Cards
Appointments
Transplant & Immunology Surgery
Primary
Contact Info
About
Copy Link
Titles
Associate Professor of Surgery (Transplant)
Biography
Laurine M. Bow, Ph.D., HCLD (ABB) is board certified in the field of Diagnostic Immunology and earned her Ph.D. in Molecular Genetics and Cell Biology from the University of Connecticut in Storrs, CT. She is Associate Professor in Surgery, Transplant Division and holds a secondary appointment in Lab Medicine. She is the Director of the Histocompatibility and Immune Evaluation laboratory, which supports all solid organ transplantation at Yale.
Dr. Bow’s research interests include clinical relevance of HLA antibodies in organ transplantation, transplant immunology, and vascular biology. In addition, new diagnostic tools for monitoring allograft rejection including donor derived cell free DNA and non-HLA antibodies in transplantation.
Last Updated on September 29, 2025.
Appointments
Transplant & Immunology Surgery
Associate Professor on TermPrimary
Other Departments & Organizations
- Surgery
- Transplant & Immunology Surgery
- Yale Medicine
Education & Training
- PhD
- University of Connecticut (1991)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Laurine Bow's published research.
Publications Timeline
A big-picture view of Laurine Bow's research output by year.
Geliang Gan, MPH, PhD
Yanhong Deng
34Publications
532Citations
Publications
2025
Cover Image, Volume 39, Issue 5
Sapir‐Pichhadze R, Askar M, Cooper M, Cornell L, Cozzi E, Dadhania D, Diekmann F, de Vries A, Schinstock C, Carroll R, Abdelrehim A, Gan G, Deng Y, Alasfar S, Bagnasco S, Batal I, Budde K, Groningen M, Kung V, Lower F, Seija M, Kraus E, Naesens M, Bow L, Group T. Cover Image, Volume 39, Issue 5. Clinical Transplantation 2025, 39 DOI: 10.1111/ctr.70184.Peer-Reviewed Original ResearchRethinking the Diagnosis and Management of Antibody‐Mediated Rejection in Multidisciplinary Transplant Meetings: A Global Survey and Banff Working Group Recommendations
Sapir‐Pichhadze R, Askar M, Cooper M, Cornell L, Cozzi E, Dadhania D, Diekmann F, de Vries A, Schinstock C, Carroll R, Abdelrehim A, Gan G, Deng Y, Alasfar S, Bagnasco S, Batal I, Budde K, Groningen M, Kung V, Lower F, Seija M, Kraus E, Naesens M, Bow L, Group T. Rethinking the Diagnosis and Management of Antibody‐Mediated Rejection in Multidisciplinary Transplant Meetings: A Global Survey and Banff Working Group Recommendations. Clinical Transplantation 2025, 39: e70167. PMID: 40294134, PMCID: PMC12036956, DOI: 10.1111/ctr.70167.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsAntibody-mediated rejectionMultidisciplinary meetingDiagnosis of antibody-mediated rejectionManagement of antibody-mediated rejectionAntibody-mediated rejection diagnosisTransplant recipientsDiagnosis revisionPatient characteristicsAcademic centersTransplant meetingsCase presentationTransplant professionalsTransplantationStandard careWorking group recommendationsTransplant programsAntibody dataDiagnosisLaboratory expertsMolecular diagnosticsImprove careTrainee educationMedical educationBanffPrimary barrier
2015
Enteric‐coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal‐transplant recipients compared with mycophenolate mofetil
Feng J, Zhang L, Zhao P, Bow L, Tian J. Enteric‐coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal‐transplant recipients compared with mycophenolate mofetil. International Journal Of Clinical Practice Supplement 2015, 69: 1-7. PMID: 26176848, DOI: 10.1111/ijcp.12660.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAdministration, OralAdultChinaDose-Response Relationship, DrugEnzyme InhibitorsFemaleFollow-Up StudiesGraft RejectionHumansImmunosuppressive AgentsIncidenceKidney TransplantationMaleMiddle AgedMycophenolic AcidProspective StudiesSurgical Wound InfectionTablets, Enteric-CoatedTacrolimusTransplant RecipientsConceptsAsian renal transplant recipientsRenal transplant recipientsEnteric-coated mycophenolate sodiumEC-MPSMycophenolate sodiumMMF groupIncidence of infectionMycophenolate mofetilSerious infectionsAdverse eventsLower incidenceTherapeutic effectLive donor kidney transplant recipientsInfection rateGastro-intestinal adverse eventsClinical trial registration numberIncidence of biopsyPosttransplant infection ratesTimes of diarrheaKidney transplant recipientsSerum creatinine levelsTRIAL REGISTRATION NUMBEREnteric-coated formulationAcute rejectionRenal transplantation
2010
A RETROSPECTIVE ANALYSIS OF THE CLINICAL SIGNIFICANCE OF SOLID PHASE ASSAY (LUMINEX) DETECTION OF PRE-TRANSPLANT HLA ANTIBODY AS MEASURED BY GRAFT OUTCOME IN RENAL TRANSPLANT RECIPIENTS
Bow L, Miller M, Alberghini T, Hull D, O'Sullivan D, Rewinski M, Lipkowitz G. A RETROSPECTIVE ANALYSIS OF THE CLINICAL SIGNIFICANCE OF SOLID PHASE ASSAY (LUMINEX) DETECTION OF PRE-TRANSPLANT HLA ANTIBODY AS MEASURED BY GRAFT OUTCOME IN RENAL TRANSPLANT RECIPIENTS. Transplantation 2010, 90: 526. DOI: 10.1097/00007890-201007272-00979.Peer-Reviewed Original Research
2001
Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization
Benedetto B, Lipkowitz G, Madden R, Kurbanov A, Hull D, Miller M, Bow L. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. Journal Of Vascular Surgery 2001, 34: 139-142. PMID: 11436087, DOI: 10.1067/mva.2001.114206.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsVein allograftsHemodialysis accessPRA valuesControl cohortPRA assaysWaiting listKidney transplantation waiting listPanel-reactive antibodies valuesPotential kidney transplant recipientsUniversity-affiliated medical centerMajor histocompatibility complex IKidney transplant recipientsHistory of transfusionTransplant waiting listTransplantation waiting listMean PRANonimmunosuppressed individualsHemodialysis populationKidney transplantationPrior transplantationTransplant recipientsConsecutive patientsProsthetic graftsAntibody valuesKidney failure
2000
Response to “A Novel United Network for Organ Sharing Region Kidney Allocation Plan Improves Transplant Access for Minority Candidates”
Hull D, Bow L, Mather J. Response to “A Novel United Network for Organ Sharing Region Kidney Allocation Plan Improves Transplant Access for Minority Candidates”. Transplantation 2000, 70: 1113. PMID: 11045655, DOI: 10.1097/00007890-200010150-00024.Commentaries, Editorials and LettersModulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection
Onyeji C, Nicolau D, Nightingale C, Bow L. Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection. Journal Of Antimicrobial Chemotherapy 2000, 46: 429-436. PMID: 10980170, DOI: 10.1093/jac/46.3.429.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsGranulocyte colony-stimulating factorG-CSFColony-stimulating factorInfected animalsNeutropenic miceFaecalis infectionDisposition of vancomycinNon-neutropenic animalsEnterococcus faecalis infectionPharmacokinetics of antibioticsInduction of neutropeniaConcentration-time curveEfficacy of gentamicinDose-dependent increaseE. faecalis infectionNeutropenic patientsPharmacokinetic interactionsDosing regimensSame infectionPlasma clearanceUseful adjunctGentamicinInfectionVancomycinMice
1999
Effectiveness of a Writing Improvement Intervention Program on the Readability of the Research Informed Consent Document
Philipson S, Doyle M, Nightingale C, Bow L, Mather J, Philipson E. Effectiveness of a Writing Improvement Intervention Program on the Readability of the Research Informed Consent Document. Journal Of Investigative Medicine 1999, 47: 468-476. PMID: 10572377, DOI: 10.1177/108155899904700905.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsConsent documentsResearch writersWritingConsent formResearch informed consentAnnotation instructionsInformed consent documentIntervention programsReadingConsentReadabilityDocumentsInformed consentReading levelWritersInstitutional review boardReading comprehension researchReview boardResearch DepartmentQuestion-by-question analysisComprehensionInfluence of adjunctive interferon-γ on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice
Onyeji C, Bui K, Nicolau D, Nightingale C, Bow L, Quintiliani R. Influence of adjunctive interferon-γ on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice. International Journal Of Antimicrobial Agents 1999, 12: 301-309. PMID: 10493606, DOI: 10.1016/s0924-8579(99)00055-2.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsIFN-gammaFaecalis infectionDisposition of gentamicinInfected neutropenic miceNon-neutropenic miceTreatment of gentamicinSerious enterococcal infectionsEnterococcus faecalis infectionNew treatment optionsE. faecalis infectionOutcome of therapyActivity of gentamicinE. faecalis clinical isolatesDose-dependent mannerPharmacokinetic interactionsConcurrent administrationDosing regimensNeutropenic miceCombination therapyInfectious burdenTreatment optionsEnterococcal infectionsIntraperitoneal inoculationClinical isolatesInfected animalsA new allocation plan for renal transplantation
Delmonico F, Harmon W, Lorber M, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Bow L, Milford E, Rohrer R. A new allocation plan for renal transplantation. Transplantation Proceedings 1999, 31: 358-359. PMID: 10083141, DOI: 10.1016/s0041-1345(98)01660-1.Peer-Reviewed Original ResearchCitations
Get In Touch
Copy Link